Cargando…

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report

Microsatellite instability-high (MSI-H) is widely believed to be a biomarker for immune checkpoint inhibitors (ICIs) such as pembrolizumab in solid tumors. However, due to the low prevalence of MSI-H in most cancers, it tends to be insufficient to identify whether patients should receive ICIs accord...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Tian, Zhang, Lei, Chen, Can, Zhao, Xiang, Liu, Xiaoqing, Ran, Fengwei, Yong, Tingting, Yang, Ying, Zhang, Henghui, Zhang, Yanling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640956/ https://www.ncbi.nlm.nih.gov/pubmed/34868995 http://dx.doi.org/10.3389/fonc.2021.767957

Ejemplares similares

Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response
por: Wilkins, Matthew C, et al.
Publicado: (2021)

Advanced Esophageal Squamous Cell Carcinoma in Young Female Patient With Durable Complete Response on Treatment
por: Jankarashvili, Natalia, et al.
Publicado: (2021)

Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab
por: Chahoud, Jad, et al.
Publicado: (2020)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
por: Senda, Masaya, et al.
Publicado: (2023)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
por: Kadota, Naoki, et al.
Publicado: (2021)

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
por: Domingo-Musibay, Evidio, et al.
Publicado: (2018)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Pembrolizumab in FIGO IVB Verrucous Carcinoma of the Vulva: A Case Report
por: Wang, Yuhan, et al.
Publicado: (2021)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
por: Yoshida, Tsukasa, et al.
Publicado: (2022)

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma
por: Spathas, Nikolaos, et al.
Publicado: (2018)

Spindle Cell Squamous Cell Carcinoma of the Scalp Treated With Pembrolizumab Cisplatin and 5-Fluorouracil
por: Alzahrani, Ali M, et al.
Publicado: (2021)

RNA Sequencing of Tumor-Educated Platelets Reveals a Three-Gene Diagnostic Signature in Esophageal Squamous Cell Carcinoma
por: Liu, Tiejun, et al.
Publicado: (2022)

Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response
por: Singh, Amisha, et al.
Publicado: (2022)

Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer
por: Kai, Yugo, et al.
Publicado: (2021)

Genomic Variations in Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma
por: Yasar, Hatime A
Publicado: (2023)

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China
por: Yang, Wenyu, et al.
Publicado: (2023)

Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis
por: Nguyen, Mike, et al.
Publicado: (2019)

Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
por: Tan, Qiaoyun, et al.
Publicado: (2022)

METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression
por: Chen, Xiaoting, et al.
Publicado: (2021)

Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
por: Porragas-Paseiro, Hector S., et al.
Publicado: (2023)

Complete Response of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-Associated Renal Cell Carcinoma to Pembrolizumab Immunotherapy: A Case Report
por: Wang, Tao, et al.
Publicado: (2021)

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report
por: Zhu, Yingying, et al.
Publicado: (2020)

A case of long-term complete remission of locally advanced T4 bladder cancer treated with pembrolizumab
por: Horibe, Yuki, et al.
Publicado: (2021)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Gu, Yi-Min, et al.
Publicado: (2022)

TRPC1 Inhibits Cell Proliferation/Invasion and Is Predictive of a Better Prognosis of Esophageal Squamous Cell Carcinoma
por: Zeng, Yun-Zhu, et al.
Publicado: (2021)

Characterization of the Immune Cell Infiltration Landscape in Esophageal Squamous Cell Carcinoma
por: Sui, Zhilin, et al.
Publicado: (2022)

Corrigendum: TRPC1 Inhibits Cell Proliferation/Invasion and Is Predictive of a Better Prognosis of Esophageal Squamous Cell Carcinoma
por: Zeng, Yun-Zhu, et al.
Publicado: (2021)

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report
por: Atiq, Mohammad O., et al.
Publicado: (2023)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021)

An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma
por: Lorenzi, Maria, et al.
Publicado: (2019)

Metabolically Supported Chemotherapy for Managing End-Stage Breast Cancer: A Complete and Durable Response
por: İyikesici, Mehmet Salih, et al.
Publicado: (2021)

A radiomics nomogram for predicting postoperative recurrence in esophageal squamous cell carcinoma
por: Tong, Yahan, et al.
Publicado: (2023)

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
por: Acero Brand, Fanny Zulay, et al.
Publicado: (2018)

Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design
por: Zheng, Yuyan, et al.
Publicado: (2021)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

EI24 Inhibits Cell Proliferation and Drug Resistance of Esophageal Squamous Cell Carcinoma
por: Duan, Lili, et al.
Publicado: (2020)

CDKL3 Targets ATG5 to Promote Carcinogenesis of Esophageal Squamous Cell Carcinoma
por: Zhou, Suna, et al.
Publicado: (2020)

Integrating Clinical and Genetic Analysis of Perineural Invasion in Head and Neck Squamous Cell Carcinoma
por: Zhang, Ze, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bdgcm5em8gb0pncnjafj06dutq